Macrocycle Therapeutics to Treat Life-threatening Diseases | Zendy

Gokhan Batur | Zendy; Philipp Ermert | Zendy; Johann Zimmermann | Zendy; Daniel Obrecht | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Macrocycle Therapeutics to Treat Life-threatening Diseases

Author(s) -

Gokhan Batur,

Philipp Ermert,

Johann Zimmermann,

Daniel Obrecht

Publication year - 2021

Publication title -

chimia international journal for chemistry

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.387

H-Index - 55

eISSN - 2673-2424

pISSN - 0009-4293

DOI - 10.2533/chimia.2021.508

Subject(s) - eribulin , medicine , antibiotics , elastase , cancer research , pharmacology , breast cancer , metastatic breast cancer , cancer , chemistry , microbiology and biotechnology , biology , biochemistry , enzyme

Polyphor's macrocycle platform led to the discovery of novel antibiotics addressing specifically Gramnegative bacteria by targeting outer membrane proteins. Furthermore, POL6014, an inhibitor of neutrophile elastase and balixafortide, a CXCR4 inhibitor have been discovered and developed from the platform. Currently a combination of balixafortide and eribulin is in Phase III clinical trial for the treatment of patients with advanced metastatic HER2-negative breast cancer.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research